Spectrum of activity:
|
Gram-positive
&
Gram-negative
|
Details of activity:
|
Of 750 clinical isolates including: MRSA, VRE, P. aeruginosa, S. pneumoniae, N. gonorrhoeae, M. catarrhalis and P. mirabilis and more, 90% of these strains were inhibited at <2µg/ml. Drug resistant strains were also tested including ciprofloxacin resistant MRSA which was inhibited at 4µg/ml. In laboratory animals, there was `00% bioavailability with long elimination time and wide distribution in tissues
|
Description:
|
Gu JW, Fang W, Chin NX, et al. The in vitro activity of CP-74,667 a new fluoroquinolone compared to toher quinolones. 31st-ICAAC 1991;339.
|
Institute where first reported:
|
Pfizer, USA
|
Year first mentioned:
|
1991
|
Highest developmental phase:
|
Preclinical
|
Development status:
|
Inactive
|